TL;DR: On July 20, 2026, TSX Venture-listed ALZAI Health Corp. (TSXV: ALZI) announced an exclusive, worldwide, sublicensable license to an AI-driven liver-disease risk-identification technology, licensed jointly from two academic/healthcare technology-transfer offices: Yeda Research and Development Co. Ltd., the tech-transfer company of the Weizmann Institute of Science, and MOR Research Applications Ltd., the tech-transfer company of Clalit Health Services, Israel’s largest healthcare provider. ALZAI will pay Yeda and MOR customary royalties on future commercialization and sublicensing revenue; no upfront payment figure was disclosed. The deal is a useful, concrete example of a joint out-license spanning a basic-research institute and a clinical healthcare system — a structure research administrators overseeing university-hospital technology transfer will recognize.
What was announced
ALZAI Health Corp., a Canadian company trading on the TSX Venture Exchange under the ticker ALZI, announced on July 20, 2026 that it had entered into an exclusive license agreement for proprietary artificial-intelligence technology designed to identify individuals at elevated risk of liver-associated disease — principally Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD, the condition formerly termed non-alcoholic fatty liver disease), along with cirrhosis and other chronic liver conditions — using routine healthcare data rather than a dedicated diagnostic test. MASLD is estimated to affect more than a third of the global adult population, per the companies’ own framing of the deal, which is consistent with how the condition is widely described in hepatology literature as a large and under-diagnosed disease burden.
The license was granted by two separate licensors acting together: Yeda Research and Development Co. Ltd. (Yeda), the technology-transfer company of the Weizmann Institute of Science, and MOR Research Applications Ltd. (MOR), the technology-transfer company of Clalit Health Services. ALZAI’s release describes the license as exclusive, worldwide, and sublicensable, covering the right to develop, commercialize, and sublicense the technology in the licensed field.
ALZAI’s chief executive officer and director, Hayim Raclaw, was quoted characterizing the deal as a platform-expansion move: “This Agreement represents a significant milestone in ALZAI’s evolution from a single-disease company into a broader artificial intelligence-driven disease risk identification platform.” ALZAI’s name and prior public disclosures center on Alzheimer’s-disease risk identification; this license is the company’s first disclosed move into a second disease area (liver disease) built on the same AI risk-identification model.
The deal structure: why a dual-licensor out-license is the notable part
For a technology-transfer audience, the structurally interesting element isn’t the AI subject matter — it’s that the license runs through two separate, independently governed technology-transfer offices simultaneously: Yeda, which manages IP arising from Weizmann Institute research (a basic-science research institute with no clinical patient population of its own), and MOR, which manages IP arising from Clalit Health Services (Israel’s largest integrated healthcare provider and the operator of the clinical/health-system data an AI risk model of this kind would plausibly have been developed or validated against). A single AI-driven clinical risk tool built jointly across a research institute and a health-system data holder is exactly the kind of co-invention or co-ownership scenario that requires an inter-institutional agreement between the two TTOs before either can jointly out-license to a third party — see CASRAI’s technology transfer process guide for how invention disclosure, ownership determination, and out-licensing typically proceed through a single TTO, and how that gets more complex once two institutions and two data-governance regimes are both party to the underlying IP.
The publicly disclosed terms follow a conventional royalty-bearing structure rather than an equity stake: ALZAI will pay Yeda and MOR royalties calculated on future commercialization revenue from products derived from the licensed technology, plus a share of any revenue ALZAI receives through further sublicensing. No upfront payment, milestone-payment schedule, or specific royalty rate was disclosed in the company’s release. That omission is typical for early-stage biotech/health-tech licensing announcements, where royalty percentages and milestone triggers are frequently kept confidential in the underlying agreement even when the fact of a deal is publicly announced — see CASRAI’s comparison of exclusive vs. non-exclusive licensing and guide to royalty rate-setting methodology for the range of structures a customary-royalties description like this one could plausibly sit within.
What wasn’t disclosed
Consistent with typical practice for this kind of announcement, several deal specifics were not made public and should not be assumed: the actual royalty rate or rate tiers; any upfront or milestone payment amounts; the field-of-use boundaries beyond liver-associated diseases; the term/duration of the license; and the underlying patent or patent-application numbers covering the licensed technology. This piece does not speculate on any of those figures — readers who need them should consult ALZAI’s SEDAR+/regulatory filings directly, where a Canadian TSXV-listed issuer’s material agreements are typically summarized in more detail than in a press release.
Why this matters for research administrators and TTOs
Individual corporate licensing announcements aren’t usually the subject of a CASRAI news post, but this one illustrates two patterns that recur across university and academic-medical-center tech transfer generally: first, that AI/software-plus-health-data inventions increasingly straddle a pure research institute and a clinical data-holding institution, which means TTOs on both sides need clear inter-institutional IP and data-use agreements in place well before an outbound licensing conversation starts, not negotiated ad hoc alongside it. Second, that royalty-plus-sublicense-revenue-share, without an equity component, remains a standard structure for institutional out-licensing to a public company even in a high-attention field like clinical AI — institutions don’t automatically take equity just because the licensee is publicly traded.
Sources
- ALZAI Health Corp., “ALZAI Health Corp. Secures Exclusive Global License for AI-Driven Liver Disease Risk Identification Technology,” news release distributed via Newsfile Corp., July 20, 2026.
- Syndicated coverage of the same release via Yahoo Finance and IRW-Press, July 20, 2026.
This article reports on a publicly announced third-party corporate transaction for research-administration audiences tracking technology-transfer practice; CASRAI has no affiliation with ALZAI Health Corp., Yeda Research and Development Co. Ltd., MOR Research Applications Ltd., Clalit Health Services, or the Weizmann Institute of Science. Deal terms not publicly disclosed by the parties are noted as undisclosed above rather than estimated.
